Indivior (NASDAQ:INDV) Shares Gap Up to $10.88

Indivior PLC (NASDAQ:INDV)’s stock price gapped up prior to trading on Thursday . The stock had previously closed at $10.88, but opened at $12.64. Indivior shares last traded at $12.93, with a volume of 182,069 shares trading hands.

Analysts Set New Price Targets

Several research firms recently commented on INDV. Piper Sandler began coverage on Indivior in a report on Tuesday. They issued an “overweight” rating and a $22.00 target price on the stock. Craig Hallum decreased their price objective on shares of Indivior from $37.00 to $24.00 and set a “buy” rating for the company in a research note on Wednesday, July 10th.

Indivior Stock Up 16.3 %

The firm has a market cap of $1.74 billion, a price-to-earnings ratio of 1,293.00 and a beta of 0.69. The firm’s 50 day moving average price is $15.26 and its two-hundred day moving average price is $17.69. The company has a debt-to-equity ratio of 23.50, a current ratio of 0.92 and a quick ratio of 0.74.

Indivior (NASDAQ:INDV) last announced its earnings results on Thursday, April 25th. The company reported $0.37 earnings per share for the quarter, missing the consensus estimate of $0.38 by ($0.01). The business had revenue of $284.00 million for the quarter, compared to analyst estimates of $300.00 million. Indivior had a return on equity of 842.72% and a net margin of 0.44%. As a group, sell-side analysts forecast that Indivior PLC will post 1.8 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in INDV. Chilton Investment Co. Inc. purchased a new position in Indivior in the fourth quarter valued at about $263,000. ADAR1 Capital Management LLC purchased a new position in Indivior in the fourth quarter valued at about $368,000. Cannon Global Investment Management LLC acquired a new stake in Indivior during the first quarter worth approximately $563,000. Campbell & CO Investment Adviser LLC boosted its position in Indivior by 2.8% during the fourth quarter. Campbell & CO Investment Adviser LLC now owns 37,948 shares of the company’s stock worth $573,000 after acquiring an additional 1,037 shares during the last quarter. Finally, Forsta AP Fonden acquired a new stake in Indivior during the first quarter worth approximately $641,000. 60.33% of the stock is owned by hedge funds and other institutional investors.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.